Overall Average: 32% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Did This Lightning-Rod Drug Go Too Far?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 2:12PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass discuss the continuing backlash from pharmacy benefits manager Express Scripts against the price point Gilead has set for its... (full story)
Final Glance: Biotechnology companies
AP - Fri May 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading: (full story)
BetterInvesting Magazine Releases July Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri May 02, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Gilead Sciences, Inc. (NDQ: GILD) as its July 2014 "Stock to Study" and Microsoft Corporation (NDQ: MSFT) as its July 2014 "Undervalued Stock" for investors' informational and educational use. (full story)
Loss at BioMarin Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 3:00PM CDT
Higher product sales narrowed first quarter loss at BioMarin (BMRN). (full story)
Shire Beats on Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:05PM CDT
Shire (SHPG) reported first quarter 2014 earnings (excluding special items and amortization) of $2.36 per American Depositary Share (ADS), up from $1.72 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.22. (full story)
Affymetrix Q1 Earnings Beat Ests by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 1:50PM CDT
Affymetrix Inc. (AFFX) reaffirmed its previously announced revenue and EBITDA guidance for 2014. (full story)
Express Scripts Earnings: 3 Things You Need to Know
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 1:30PM CDT
Express Scripts investors had a rough day Tuesday, as a surprised market cut 6% from the company's value after a disappointing first quarter earnings report. There were three huge areas of concern for investors, but first let's talk about the... (full story)
Midday Glance: Biotechnology companies
AP - Fri May 02, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.: (full story)
Novo Nordisk Beats Earnings Ests, Misses Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:10AM CDT
Novo Nordisk reported 1Q14 earnings of 45 cents per ADR, beating the Zacks Consensus Estimate of 44 cents (full story)
Wider-than-Expected Q1 Loss at Incyte - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:00AM CDT
Incyte's (INCY) loss of 21 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate of a loss of 19 cents. (full story)
Early Glance: Biotechnology companies
AP - Fri May 02, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.: (full story)
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery. (full story)
Can the Rally in Gilead (GILD) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:41AM CDT
Can the Rally in Gilead (GILD) Shares Continue? (full story)
Earnings Estimates Moving Higher for Gilead (GILD): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:58AM CDT
Gilead may be an interesting play for investors, as it is seeing solid activity on the earnings estimate revision front (full story)
Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day (full story)
Jim Cramer's 'Mad Money' Recap: Unsafe at Any Price
at The Street - Thu May 01, 7:00PM CDT
Big money managers are once again shifting direction, Cramer says. (full story)
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained? (full story)
'Mad Money' Lightning Round: Buy, Buy, Buy Gilead Sciences
at The Street - Fri May 02, 5:00AM CDT
Cramer says don't buy Ensco International and Quidel, beware of Gogo but buy more Boeing. (full story)
Vertex ends hepatitis C investment as sales fall
AP - Thu May 01, 6:27PM CDT
NEW YORK (AP) — Vertex Pharmaceuticals, which reported more than $1 billion in sales of its hepatitis C drug Incivek in 2012, said Thursday it won't invest any more money on research and development of new treatments for the disease. (full story)